Small businesses may be likely to consider reducing employee benefits, especially those related to GLP-1, or shifting a greater percentage of healthcare costs to employees
Semaglutide is the same core drug behind three global brands:[8][3] Ozempic (injectable) approved in 2017 for type 2 diabetes, onceweekly injection.[9][3] Wegovy (higherdose injectable) approved in 2021 for chronic weight management, using larger doses of the same drug.[10][11] Rybelsus (oral tablet) an oral version of semaglutide, approved around 2019 for diabetes.[3][8] Clinically, the trials showed strong reductions in HbA1c and substantial weight loss versus older diabetes drugs and earlier weightloss pills.[12][13] Commercially, each brand got its own positioning, campaigns and, importantly, slightly different regulatory labels and patent wrapping.[14][15] Key point: One discovery was sliced into multiple brands and indications, each with its own story, price and protection
Available in 5mg, 10mg, and 50mg lyophilized vials
4.65 / 9.09
NPY stimulates food intake by increasing hunger and promoting fat storage, while galanin has the opposite effect by suppressing appetite